Arno Nolting

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

Gunnar Folprecht, Manfred P. Lutz, Patrick Schöffski et al. · Annals of Oncology · 2005 · 233 citations · Full text

Oncology, Medicine, Colorectal Cancer +7

Characterization of Complexes of Oligonucleotides with Polyamidoamine Starburst Dendrimers and Effects on Intracellular Delivery

Robert K. DeLong, Katherine Stephenson, Todd Loftus et al. · Journal of Pharmaceutical Sciences · 1997 · 132 citations

Safety of Hydroxocobalamin in Healthy Volunteers in a Randomized, Placebo-Controlled Study

Wolfgang Uhl, Arno Nolting, Georg Golor et al. · Clinical Toxicology · 2006 · 112 citations

Population Pharmacokinetics of Cetuximab in Patients With Squamous Cell Carcinoma of the Head and Neck

Nathanae L. Dirks, Arno Nolting, Andreas Kovar et al. · The Journal of Clinical Pharmacology · 2008 · 81 citations

Pharmacokinetic profile of cetuximab (Erbitux™) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma

Catherine Delbaldo, Jean‐Yves Pierga, Véronique Dièras et al. · European Journal of Cancer · 2005 · 80 citations

Oncology, Pharmacokinetic Profile, Medicine +7